Advertisement

Practical Aspects of Prostaglandin E1 before and after Solid Organ Transplantation

  • H. Müller
  • A. Wasler
  • B. Petutschnigg
  • T. Allmayer
  • B. Grasser
  • G. Prenner
  • S. Schaffellner
  • KH. Tscheliessnigg
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 433)

Abstract

Prostaglandins and analogues for therapeutic use gained importance in the early eighties, when a substantial number of clinical studies about their therapeutical effects was published6, 12, 17, 22. Out of the huge family of prostanoids, prostaglandins E1 (PG E1) and I2 and their synthetical analogues are the most important substances in clinical practice in the field of solid organ transplantation. Organ procurement and organ preservation4, 5, 9, 15, 19 as well as treatment of primary graft failure8, 10 have been described as possible indications for PG E1. Vasodilating effects of prostaglandins are mediated by increasing cAMP levels in vascular smooth muscle cells. This mediation by cAMP is shared with beta-agonists and phosphodiesterase-inhibitors, but not with nitrates and nitric oxide3, 14, 21. Treatment of elevated pulmonary vascular resistance (PVR), which is frequently needed after heart transplantation (HTX), and in the pretransplant evaluation as well as bridging to transplan-tation1, 7, 20 has been the indication for PG E1 in our patient cohort.

Keywords

Pulmonary Hypertension Systemic Vascular Resistance Solid Organ Transplantation Primary Pulmonary Hypertension Heart Lung Transplant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Armitage G., Hardesty R. et al., Prostaglandin E1: An effective treatment of right heart failure after cardiac transplantation. J Heart Transplant 6:348–51 (1987)PubMedGoogle Scholar
  2. 2.
    Cawello W., Leonhardt A., Schweer H. et al, Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. Br J Pharmacol. 40(3): 273–6 (1995)CrossRefGoogle Scholar
  3. 3.
    Fullerton D., Hahn A. et al, Pulmonary vascular smooth muscle cell relaxation by cGMP-versus cAMP-mediated mechanisms. J Surg Res. 57(2): 259–63 (1994)PubMedCrossRefGoogle Scholar
  4. 4.
    Harjula A., Baldwin J. et al, Clinical heart lung preservation with Prostaglandin E1. Transpl Proc. 19: 4101 (1987)Google Scholar
  5. 5.
    Hide EJ., Ney P., Piper J. et al., Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. BrJ Pharmacol. 116(5): 2435–40 (1995)CrossRefGoogle Scholar
  6. 6.
    Higenbottam T, Wheeldon D et al., Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (Prostacyclin). Lancet 12: 1046–7 (1984)CrossRefGoogle Scholar
  7. 7.
    Iberer F., Wasler A. et al., Prostaglandin E1 induced moderation of elevated pulmonary vascular resistance. Survival on waiting list and results of orthotopic heart transplantation. J Heart Lung Transplant 12(2): 173–8 (1993)PubMedGoogle Scholar
  8. 8.
    Iberer F., Müller H. et al., Prostaglandin E1 in der Therapie der Abstoßung und des pulmonalen Hypertonus im Rahmen der Herztransplantation. Immundiagnostik und Immuntherapie in der modernen Intensivmedizin, Vogt S., ed., Pabst-Verlag, Lengerich (1993)Google Scholar
  9. 9.
    Kim Y., Kai T. et al., Hepatoprotection by a PG I2 analogue in complete wann ischemia of the pig liver. Prostanoid release from the reperfused liver. Transplantation 58(8): 875–9 (1994)PubMedCrossRefGoogle Scholar
  10. 10.
    Moran M., Mozes M. et al., Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. N Engl J Med. 322: 1183–88 (1990)PubMedCrossRefGoogle Scholar
  11. 11.
    Murali S., Uretsky B., Armitage J. et al., Utility of Prostaglandin E1 in the Pretransplantation Evaluation of Heart Failure Patients with Significant Pulmonary Hypertension. J Heart Lung Transplant. 11: 716–23(1991)Google Scholar
  12. 12.
    Naeije R., Melot C et al., Reduction in pulmonary hypertension by prostaglandin E1 in decompensated chronic obstructive pulmonary disease. Am Rev Despir Dis. 125: 1–5 (1982)Google Scholar
  13. 13.
    Pacher R., Globits S., Wutte M. et al., Beneficial hemodynamic effects of prostaglandin E1 infusion in catecholamine-dependent heart failure: results of a prospective, randomized controlled study. Crit Care Med. 22(7): 1084–90 (1994)PubMedCrossRefGoogle Scholar
  14. 14.
    Prielipp R., McLean R. et al., Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin and nifedipin in experimental porcine pulmonary hypertension. Crit Care Med. 19(1): 60–7 (1991)PubMedCrossRefGoogle Scholar
  15. 15.
    Quiroga J., Prieto J., Liver cytoprotection by prostaglandins. Pharmacol Ther. 58(1): 67–91 (1993)PubMedCrossRefGoogle Scholar
  16. 16.
    Schweer H., Cawello W., Seyberth HW, Gas chromatogryphy negative ion chemical ionization triple quadrupole mass spectometric determination and pharmacokinetics of 11 alpha-hydroxy-9,15-dioxo-2, 3, 4, 5, 20-pentanor-19-carboprostanoic acid in plasma. Prostaglandins Leukot Essent Fatty Acids. 51(6): 401–5(1994)PubMedCrossRefGoogle Scholar
  17. 17.
    Sinzinger H., Rogatti W., Prostaglandin E1 in der Therapie der peripheren arteriellen Durchblutungsstörung. Wiener Klinische Wochenschrift 103/18: 558–565 (1991)PubMedGoogle Scholar
  18. 18.
    Sorbara C, Pitarello D. et al., Prostaglandine in der Intensivmedizin und bei Herztransplantationen. Translation from A.P.I. C.E; Vol. 8: 327–337 (1993)Google Scholar
  19. 19.
    Ueno T., Horita K. et al., The effect of Prostaglandin E1 on heart preservation. Transplantation 54(3): 418–22 (1992)PubMedCrossRefGoogle Scholar
  20. 20.
    Vincent J., Carlier E. et al., Prostaglandin E1 infusion for right ventricular failure after after cardiac transplantation. J Thorac Cardiovasc Surgery. 103: 33–39 (1992)Google Scholar
  21. 21.
    Warren J., Wilson A. et al., Opposing roles of cyclic AMP in the vascular control of edema formation. FASEB J. 7(14): 1394–400 (1993)PubMedGoogle Scholar
  22. 22.
    Watkins W., Peterson M. et al., Prostacyclin and Prostaglandin E1 for severe idiopathic pulmonary hypertension. Lancet I. 1083 (1981)Google Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • H. Müller
    • 1
  • A. Wasler
    • 1
  • B. Petutschnigg
    • 1
  • T. Allmayer
    • 1
  • B. Grasser
    • 1
  • G. Prenner
    • 1
  • S. Schaffellner
    • 1
  • KH. Tscheliessnigg
    • 1
  1. 1.Department of Transplantation SurgeryKarl-Franzens-University GrazGrazAustria

Personalised recommendations